Table II.
Regulatory associations between hsa-miR-17 and its target genes.
| Genes that regulate hsa-miR-17 | Target genes of hsa-miR-17 | ||||
|---|---|---|---|---|---|
| Differentially expressed network | Associated network | Global network | Differentially expressed network | Associated network | Global network |
| CCND1 | CCND1 | CCND1 | BCL2 | BCL2 | APP, BCL2, BCL2L11 |
| MYC | E2F1 | CCND1 | CCND1 | BMPR2, CCL1, CCND1 | |
| MIR17HG | RBL2 | RBL2 | CCND2, CDKN1A, DNAJC27 | ||
| MYC | VEGFA | VEGFA | E2F1, E2F3, FBXO31 | ||
| MYCN | TGFBR2 | TGFBR2 | GPR137B, GPX2, ICAM1 | ||
| NFKB1 | MYC | JAK1, MAP3K12, MAPK9 | |||
| NKX2–5 | MEF2D, MUC17, MYC | ||||
| SPI1 | NCOA3, NPAT, OBFC2A | ||||
| STAT5B | PKD2, PTEN, PTPRO | ||||
| TLX1 | RB1, RBL1, RBL2 | ||||
| TLX3 | RUNX1, SELE, SMAD4 | ||||
| TNF | SOD2, TGFBR2, THBS1 | ||||
| TNFSF12, TXNRD2, VEGFA | |||||
| VIM, WEE1, YES1, ZNFX1 | |||||
miR, microRNA; hsa, Homo sapiens; CCND1, cyclin D1; MYC, v-Myc avian myelocytomatosis viral oncogene homolog; E2F1, E2F transcription factor 1; HG, host gene; MYCN, v-Myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog; NFKB1, nuclear factor of kappa light polypeptide gene enhancer in B-cells 1; NKX2–5, NK2 homeobox 5; SPI1, spleen focus forming virus proviral integration oncogene Spi1; STAT5B, signal transducer and activator of transcription 5B; TLX1, T-cell leukemia homeobox 1; TLX3, T-cell leukemia homeobox 3; TNF, tumor necrosis factor; BCL2, B-cell lymphoma 2; RBL2, retinoblastoma-like 2; VEGFA, vascular endothelial growth factor A; TGFBR2, transforming growth factor, beta receptor II; APP, amyloid precursor protein; BCL2L11, BCL2-like 11; BMPR2, bone morphogenetic protein receptor type II; CCL1, chemokine (C-C motif) ligand 1; CCND2, cyclin D2; CDKN1A, cyclin-dependent kinase inhibitor 1A; DNAJC27, DnaJ (Hsp40) homolog, subfamily C, member 27; E2F3, E2F transcription factor 3; FBXO31, F-box protein 31; GPR137B, G protein-coupled receptor 137B; GPX2, glutathione peroxidase 2; ICAM1, intercellular adhesion molecule 1; JAK1, Janus kinase 1; MAP3K12, mitogen-activated protein kinase kinase kinase 12; MAPK9, mitogen-activated protein kinase 9; MEF2D, myocyte enhancer factor 2D; MUC17, mucin 17; NCOA3, nuclear receptor coactivator 3; NPAT, nuclear protein, ataxia-telangiectasia locus; OBFC2A, oligonucleotide/oligosaccharide-binding fold-containing protein 2A; PKD2, polycystic kidney disease 2; PTEN, phosphatase and tensin homolog; PTPRO, protein tyrosine phosphatase receptor type O; RB1, retinoblastoma 1; RBL1, retinoblastoma-like 1; RBL2, retinoblastoma-like 2; RUNX1, runt-related transcription factor 1; SELE, selectin E; SMAD4, SMAD family member 4; SOD2, superoxide dismutase 2, mitochondrial; THBS1, thrombospondin 1; TNFSF12, tumor necrosis factor (ligand) superfamily, member 12; TXNRD2, thioredoxin reductase 2; VIM, vimentin; WEE1, WEE1 G2 checkpoint kinase; YES1, YES proto-oncogene 1, Src family tyrosine kinase; ZNFX1, zinc finger, NFX1-type containing 1.